文献速递艾滋病与性传播感染

广谱中和抗体VRC07-523LS联合伏立诺他治疗下潜伏HIV感染与低水平病毒血症稳定

Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
PubMed 文献 · J Infect Dis · 2022-01-01

本研究测试广谱中和HIV抗体VRC07-523LS联合潜伏逆转剂伏立诺他(VOR)的疗效。8名参与者接受2个为期1个月的VRC07-523LS联合VOR治疗周期,检测低水平病毒血症、静息CD4+ T细胞相关HIV RNA(rca-RNA),并在基线和治疗后进行完整前病毒DNA检测(IPDA)和定量病毒生长检测(QVOA)。结果显示该联合治疗未降低病毒血症或HIV储存库。

要点

  • VRC07-523LS联合伏立诺他未降低病毒血症或HIV储存库。
  • 3名参与者IPDA和QVOA下降伴随rca-RNA显著下降,但未超出检测变异或自然衰减。
  • 未观察到对VRC07-523LS的耐药性增加。

核心结论

  • VRC07-523LS联合伏立诺他治疗未降低病毒血症或HIV储存库。

研究设计与样本

  • 8名参与者接受2个为期1个月的VRC07-523LS联合伏立诺他治疗周期。
  • 在基线和治疗后测量低水平病毒血症、静息CD4+ T细胞相关HIV RNA(rca-RNA),并进行完整前病毒DNA检测(IPDA)和定量病毒生长检测(QVOA)。

主要发现

  • 3名参与者中IPDA和QVOA下降伴随rca-RNA显著下降。
  • 没有任何IPDA或QVOA下降明确超过检测变异或自然衰减。
  • 未观察到对VRC07-523LS的耐药性增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell-associated HIV RNA (rca-RNA) was measured, and intact proviral DNA assay (IPDA) and quantitative viral outgrowth assay (QVOA) were performed at baseline and posttreatment. In 3 participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natural decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir. Clinical Trials Registration. NCT03803605.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gay CL, James KS, Tuyishime M, et al. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. J Infect Dis. 2022. PMID: 34562096. doi:10.1093/infdis/jiab487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。